{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T22:43:51Z","timestamp":1785797031795,"version":"3.56.0"},"reference-count":19,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,8]],"date-time":"2022-12-08T00:00:00Z","timestamp":1670457600000},"content-version":"vor","delay-in-days":494,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["rpthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Research and Practice in Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1002\/rth2.12574","type":"journal-article","created":{"date-parts":[[2021,9,15]],"date-time":"2021-09-15T00:47:12Z","timestamp":1631666832000},"page":"e12574","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Thrombosis in myeloproliferative neoplasms: Treatment outcomes of direct oral anticoagulants and vitamin K antagonists"],"prefix":"10.1016","volume":"5","author":[{"given":"Kateryna","family":"Fedorov","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swati","family":"Goel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarita","family":"Kushnir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henny H.","family":"Billett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1002\/rth2.12574_bb0010","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1182\/blood-2016-10-695957","article-title":"Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms","volume":"129","author":"Rumi","year":"2017","journal-title":"Blood"},{"issue":"13","key":"10.1002\/rth2.12574_bb0015","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1182\/blood-2013-03-460154","article-title":"Myeloproliferative neoplasms and thrombosis","volume":"122","author":"Barbui","year":"2013","journal-title":"Blood"},{"issue":"6","key":"10.1002\/rth2.12574_bb0020","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/ajh.23690","article-title":"How common are myeloproliferative neoplasms? A systematic review and meta\u2010analysis","volume":"89","author":"Titmarsh","year":"2014","journal-title":"Am J Hematol"},{"issue":"7","key":"10.1002\/rth2.12574_bb0025","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1111\/jth.12265","article-title":"Thrombotic complications of myeloproliferative neoplasms: risk assessment and risk\u2010guided management","volume":"11","author":"Casini","year":"2013","journal-title":"J Thromb Haemost"},{"issue":"5","key":"10.1002\/rth2.12574_bb0030","doi-asserted-by":"crossref","first-page":"317","DOI":"10.7326\/M17-0028","article-title":"Risk for arterial and venous thrombosis in patients with myeloproliferative neoplasms: a population\u2010based cohort study","volume":"168","author":"Hultcrantz","year":"2018","journal-title":"Ann Intern Med"},{"key":"10.1002\/rth2.12574_bb0035","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.2147\/PPA.S204246","article-title":"Comparing quality of life and treatment satisfaction between patients on warfarin and direct oral anticoagulants: a cross\u2010sectional study","volume":"13","author":"Ng","year":"2019","journal-title":"Patient Prefer Adherence"},{"key":"10.1002\/rth2.12574_bb0040","doi-asserted-by":"crossref","first-page":"79","DOI":"10.2147\/PPA.S131158","article-title":"Real\u2010life experience of quality of life, treatment satisfaction, and adherence in patients receiving oral anticoagulants for atrial fibrillation","volume":"12","author":"Benzimra","year":"2018","journal-title":"Patient Prefer Adherence"},{"issue":"7","key":"10.1002\/rth2.12574_bb0045","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1056\/NEJMoa1711948","article-title":"Edoxaban for the treatment of cancer\u2010associated venous thromboembolism","volume":"378","author":"Raskob","year":"2018","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1002\/rth2.12574_bb0050","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1200\/JCO.2018.78.8034","article-title":"Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT\u2010D)","volume":"36","author":"Young","year":"2018","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1002\/rth2.12574_bb0055","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1055\/s-0038-1668523","article-title":"Apixaban versus dalteparin for the treatment of acute venous yhromboembolism in patients with cancer: the Caravaggio study","volume":"118","author":"Agnelli","year":"2018","journal-title":"Thromb Haemost"},{"key":"10.1002\/rth2.12574_bb0060","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13045-016-0242-9","article-title":"Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL\u2010MPN\u2010registry","volume":"9","author":"Kaifie","year":"2016","journal-title":"J Hematol Oncol"},{"issue":"10","key":"10.1002\/rth2.12574_bb0065","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1038\/leu.2016.85","article-title":"High rate of recurrent venous thromboembolism in patients with myeloproliferative neoplasms and effect of prophylaxis with vitamin K antagonists","volume":"30","author":"De Stefano","year":"2016","journal-title":"Leukemia"},{"issue":"3","key":"10.1002\/rth2.12574_bb0070","doi-asserted-by":"crossref","first-page":"e79","DOI":"10.1111\/bjh.16485","article-title":"Outcomes of patients receiving direct oral anticoagulants for myeloproliferative neoplasm\u2010associated venous thromboembolism in a large tertiary centre in the UK","volume":"189","author":"Curto\u2010Garcia","year":"2020","journal-title":"Br J Haematol"},{"issue":"Suppl 1","key":"10.1002\/rth2.12574_bb0075","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1182\/blood-2020-139229","article-title":"Direct oral anticoagulants for myeloproliferative neoplasms (MPN\u2010DOACs): results from an international study on 442 patients","volume":"136","author":"Barbui","year":"2020","journal-title":"Blood"},{"issue":"4","key":"10.1002\/rth2.12574_bb0080","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s12185-017-2282-5","article-title":"Administration of direct oral anticoagulants in patients with myeloproliferative neoplasms","volume":"106","author":"Ianotto","year":"2017","journal-title":"Int J Hematol"},{"issue":"6","key":"10.1002\/rth2.12574_bb0085","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.blre.2016.06.001","article-title":"The 2016 revision of WHO classification of myeloproliferative neoplasms: clinical and molecular advances","volume":"30","author":"Barbui","year":"2016","journal-title":"Blood Rev"},{"issue":"11","key":"10.1002\/rth2.12574_bb0090","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1111\/jth.13140","article-title":"Subcommittee on Control of Anticoagulation. Definition of clinically relevant non\u2010major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non\u2010surgical patients: communication from the SSC of the ISTH","volume":"13","author":"Kaatz","year":"2015","journal-title":"J Thromb Haemost"},{"key":"10.1002\/rth2.12574_bb0095","doi-asserted-by":"crossref","first-page":"4183","DOI":"10.1182\/blood-2019-128170","article-title":"Outcomes of patients receiving direct oral anticoagulants for myeloproliferative neoplasm associated venous thromboembolism","volume":"134","author":"Doyle","year":"2019","journal-title":"Blood"},{"issue":"8","key":"10.1002\/rth2.12574_bb0100","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1007\/s00277-020-04350-6","article-title":"Direct oral anticoagulants (DOAC) for prevention of recurrent arterial or venous thromboembolic events (ATE\/VTE) in myeloproliferative neoplasms","volume":"100","author":"Huenerbein","year":"2021","journal-title":"Ann Hematol"}],"container-title":["Research and Practice in Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/rth2.12574","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/rth2.12574","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S247503792201439X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S247503792201439X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/rth2.12574","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T12:22:17Z","timestamp":1762863737000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S247503792201439X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":19,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["S247503792201439X"],"URL":"https:\/\/doi.org\/10.1002\/rth2.12574","relation":{},"ISSN":["2475-0379"],"issn-type":[{"value":"2475-0379","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Thrombosis in myeloproliferative neoplasms: Treatment outcomes of direct oral anticoagulants and vitamin K antagonists","name":"articletitle","label":"Article Title"},{"value":"Research and Practice in Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1002\/rth2.12574","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2021 The Authors. Research and Practice in Thrombosis and Haemostasis published by ELSEVIER INC. on behalf of International Society on Thrombosis and Haemostasis","name":"copyright","label":"Copyright"}],"article-number":"e12574"}}